Type 2 diabetes:assessing the relative risks and benefits of glucose-lowering medications

Bergenstal, Richard M.; Bailey, Clifford J. and Kendall, David M. (2010). Type 2 diabetes:assessing the relative risks and benefits of glucose-lowering medications. American Journal of Medicine, 123 (4), 374.e9-374.e18.

Abstract

The selection of appropriate pharmacologic therapy for any disease requires a careful assessment of benefit and risk. In the case of type 2 diabetes, this decision typically balances the benefits accrued from improved glycemic control with the risks inherent in glucose-lowering medications. This review is intended to assist therapeutic decision-making by carefully assessing the potential benefit from improved metabolic control relative to the potential risks of a wide array of currently prescribed glucose-lowering agents. Wherever possible, risks and benefits have been expressed in terms of absolute rates (events per 1000 patient-years) to facilitate cross-study comparisons. The review incorporates data from new studies (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation, Action to Control Cardiovascular Risk in Diabetes, and the Veterans Affairs Diabetes Trial), as well as safety issues associated with newer glucose-lowering medications. © 2010 Elsevier Inc. All rights reserved.

Publication DOI: https://doi.org/10.1016/j.amjmed.2009.07.017
Divisions: Life & Health Sciences > Biosciences
Life & Health Sciences > Applied Health Research Group
Life & Health Sciences > Biomedical Sciences research group
Related URLs:
Uncontrolled Keywords: age distribution,blood glucose,type 2 diabetes mellitus,humans,hypoglycemic agents,risk factors,Medicine(all)
Published Date: 2010-04

Download

Full text not available from this repository.

Export / Share Citation


Statistics

Additional statistics for this record